Pharma Journalist -

BioMarin Pharmaceutical Inc. and Inozyme Pharma, Inc. announced that BioMarin has entered into a definitive agreement to acquire Inozyme for $4.00 per share in an all-cash transaction…
Read More...

Bristol Myers Squibb announced that the European Commission (EC) has approved the perioperative regimen of neoadjuvant Opdivo (nivolumab) and chemotherapy followed by surgery and…
Read More...

Pfizer Inc. announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese biopharmaceutical company, for the…
Read More...

The Microbiome Movement Summit returns in 2025 for its milestone 10th edition, marking a decade of groundbreaking progress and collaborative advancement in microbiome science. This…
Read More...

Septerna, Inc. and Novo Nordisk announced an exclusive global collaboration and license agreement to discover, develop and commercialise oral small molecule medicines for obesity, type…
Read More...

BioCryst Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for the use of oral, once-daily ORLADEYO …
Read More...

AbbVie announced that EMRELIS (telisotuzumab vedotin-tllv) has been granted accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with…
Read More...

Stylus Medicine, Inc. (“Stylus”), a biotechnology company dedicated to developing transformative in vivo genetic medicines, emerges from stealth with $85 million in financing. Stylus’…
Read More...

GSK plc and Boston Pharmaceuticals announced that they have entered into an agreement under which GSK will acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa. Efimosfermin is…
Read More...

Tempus AI, Inc. announced a new strategic collaboration to advance Boehringer Ingelheim’s growing cancer pipeline. The new, multi-year collaboration builds on foundational work the two…
Read More...